James R. Tobin - 04 Mar 2022 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role
Director
Signature
/s/ Jason Cavalier, Attorney-in-Fact for James R. Tobin
Issuer symbol
LYRA
Transactions as of
04 Mar 2022
Net transactions value
$0
Form type
4
Filing time
08 Mar 2022, 15:26:49 UTC
Previous filing
31 Jan 2022
Next filing
10 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYRA Stock Option Award $0 +14,500 $0.000000 14,500 04 Mar 2022 Common Stock 14,500 $4.77 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests and becomes exercisable in 36 substantially equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following March 4, 2022.